Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + EP Chemotherapy Followed by Atezolizumab + Anlotinib in Extensive-stage Small Cell Lung Cancer (Real-world, Single-arm Study)
ChiCTR2400088866Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atezolizumab in small cell lung cancer (SCLC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Progression-free survival. Started Aug 2024; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400088866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088866.